Results 181 to 190 of about 9,750,144 (291)

Rhenium-186-labeled <i>ortho</i>-hydroxythiobenzhydrazide: a potential theranostic agent for use in metastatic breast cancer. [PDF]

RSC Adv
Mitra A, Chakraborty A, Upadhye T, Sahu S, Tawate M, Chakraborty S, Chakravarty R, Vimalnath KV, Kar S, Sengupta D, Gangopadhyay S, Goswami S, Gangopadhyay PK, Banerjee S.   +13 more
europepmc   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Influence of Peptide-Based Chelator Sequences on HER2-Targeting Radiopeptide. [PDF]

J Pept Sci
Gupta S, Kumar M, Repaka KM, Das A, Kengar AA, Satpati D.   +5 more
europepmc   +1 more source

Deciphering transcriptional plasticity in pancreatic ductal adenocarcinoma reveals alterations in sensory neuron innervation

Molecular Oncology, EarlyView.
Pancreatic sensory neurons innervating healthy and PDAC tissue were retrogradely labeled and profiled by single‐cell RNA sequencing. Tumor‐associated innervation showed a dominant neurofilament‐positive subtype, altered mitochondrial gene signatures, and reduced non‐peptidergic neurons.
Elena Genova, Michele Montrone, Uday Rangaswamy, Francesco Diversi, Irene Schiavo, Denise Ferrarini, Roberta Di Florio, Irene Longo, Michele Coscia, Nicola Zamboni, Giorgia Demontis, Lisa Veghini, Vincenzo Corbo, Remo Sanges, Paul Heppenstall   +14 more
wiley   +1 more source

Temporal Reproducibility of a Genetic Algorithm-Derived Health Risk Score: Standardized Out-of-Fold Validation Framework (2021-2023). [PDF]

JMIR Bioinform Biotechnol
Aoki Y, Takeda H, Yokota K, Yoshida R.
europepmc   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Nanoassembly-enabled aqueous solid-phase peptide synthesis (ASPPS): a practical DMF-free approach based on the Fmoc strategy. [PDF]

RSC Adv
Hojo K, Nonaka A, Manabe Y, Rentier C, Mehrotra A, Hioki K, Kunishima M.   +6 more
europepmc   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Design and rationale of the SPARC trial: a phase II, single-system randomized controlled trial of immediate transfer to specialty post-arrest care. [PDF]

Resusc Plus
Elmer J, DiFiore-Sprouse S, Guyette FX, Patterson CG, Ventz S, Callaway CW, University of Pittsburgh Post-Cardiac Arrest Service.   +6 more
europepmc   +1 more source